Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Otolaryngol Pol ; 70(2): 6-12, 2016 Apr 30.
Article de Anglais | MEDLINE | ID: mdl-27392388

RÉSUMÉ

BACKGROUND: Allergic and chronic rhinosinusitis is a disabling pathological condition with an 8% prevalence in the European population and 5% in the Italian one. The ethmoidal sinus is the first one involved in the inflammation. The typical surgical procedure to manage ethmoidal sinusitis is an endoscopic antero-posterior ethmoidectomy. Recently introduced on the European market balloon called Relieva Stratus MicroFlow Spacer can be inserted within the ethmoid, with a local slow release of a steroid drug. This study had the aim to evaluate the efficacy and safety of the steroid-eluting ethmoidal stent in the management of allergic chronic rhinosinusitis in comparison with the traditional endoscopic ethmoidectomy. Methodos: 70 allergic patients who presented chronic rhinosinusitis were randomly divided into 2 groups and receive respectively the steroid-eluting ethmoidal stent or endoscopic ethmoidectomy. RESULTS: The most significant observation coming from the comparative analysis of the results is the substantial equivalence of the treatment with the steroid-eluting ethmoidal stent (SEES) compared with endoscopic ethmoidectomy in the management of ethmoid chronic rhinosinusitis with the exception of a reduction of overall discomfort and nasal secretion and better functional results at rhinomanometry in the steroid-eluting ethmoidal stent group. CONCLUSION: in our experience, the SEES was efficacious in the treatment of allergic patients with ethmoidal CRS when conventional medical treatment had failed, or when wishing to avoid the classic endoscopic ethmoidectomy (EE). However, further long-term studies will be performed in order to confirm the safety and stability, over time, of the results obtained.


Sujet(s)
Endoprothèses à élution de substances , Endoscopie , Sinus ethmoïdal/chirurgie , Rhinite/traitement médicamenteux , Rhinite/chirurgie , Sinusite/traitement médicamenteux , Sinusite/chirurgie , Stéroïdes/administration et posologie , Adulte , Sujet âgé , Anti-inflammatoires/administration et posologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Sécurité des patients , Résultat thérapeutique
2.
Am J Rhinol Allergy ; 28(2): 164-8, 2014.
Article de Anglais | MEDLINE | ID: mdl-24717954

RÉSUMÉ

BACKGROUND: Allergic rhinitis (AR) presents as the main and most invasive symptom in the blocking of the nose. This condition is almost always related to hypertrophy of the inferior turbinates. When the medical treatments are found to be insufficient to solve the obstructive symptom of the patient, the quality of life is considerably impaired and it is often necessary to submit the patient to a surgical approach. In the present study we aimed to establish the efficacy and safety of a new technique recently introduced for the shrinkage of hypertrophic turbinates using a specific device, based on a new radiofrequency energy that does not produce thermal mucosal damage, viz., quantic molecular resonance (QMR) in a group of patients with persistent moderate-severe allergic rhinitis, in addition to standard medical treatment (nasal steroid and oral antihistamine). METHODS: All patients were randomly assigned to two homogeneous groups (group A, control subjects; group B, treated patients); each group included 145 individuals. During the study, both groups received standard medications (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day) for 90 days. Before the medical treatment, patients in group B underwent inferior endoscopic turbinoplasty using QMR. All of the patients enrolled in this study were submitted to a complete otorhinolaryngologic evaluation with objective clinical examination (basal rhinomanometry, nasal provocation test rhinomanometry, and mucociliary transport time), endoscopy, and questionnaires (22-item Sino-Nasal Outcome Test and visual analog scale for nasal symptoms). RESULTS: Greater efficacy has been achieved using a combined approach with the association of medical and QMR treatment, compared with medical treatment alone, in the control of AR associated with hypertrophy of the inferior turbinates, in particular in the reduction of turbinate volume at rhinoendoscopy. CONCLUSION: QMR inferior turbinoplasty, in conjunction with medical therapy, improves the nasal flow, without any thermal mucosal damage, more effectively when compared with medical treatment alone in persistent moderate-to-severe AR. In particular, local reactivity, as measured with nasal provocation test, was noticeably reduced.


Sujet(s)
Endoscopie , Traitement par radiofréquence pulsée , Rhinite allergique/radiothérapie , Cornets/chirurgie , Adulte , Budésonide/administration et posologie , Butyrophénones/administration et posologie , Association thérapeutique , Évolution de la maladie , Femelle , Antihistaminiques/usage thérapeutique , Humains , Hypertrophie , Mâle , Tests de provocation nasale , Pipéridines/administration et posologie , Radiothérapie adjuvante , Récidive , Rhinite allergique/traitement médicamenteux , Stéroïdes/usage thérapeutique , Enquêtes et questionnaires , Résultat thérapeutique , Cornets/anatomopathologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...